SYRE Stock Forecast & Price Target

Spyre Therapeutics is supported by a differentiated, combination-first pipeline that spans in-house anti-α4β7, anti-TL1A, and anti-IL-23 assets, giving it multiple independent mechanisms with meaningful additive potential in ulcerative colitis and Crohn’s disease. Its clinical proof points are encouraging: SPY003 met the primary endpoint in Phase 2 with a 10.0-point RHI reduction at Week 12, 20% clinical remission, and 30% endoscopic improvement in 44 treated patients, while SPY072’s HS program is de-risked by strong tulisokibart readthrough, 10x potency, and 3x half-life. The thesis is further strengthened by expansion into underserved dermatology and rheumatology markets, where the US HS market is expected to grow from ~$2B per year in 2024 to >$10B by the mid-2030s, supporting long-term commercial upside.

Spyre Therapeutics is facing meaningful regulatory risk because accelerated approval strategies may still require additional data, longer studies, or changing requirements from regulators, any of which could delay development and raise costs. Its commercial prospects are also uncertain, since weaker-than-expected product labels could limit market traction even if approvals are obtained, and competitor updates may shift investor sentiment in either direction. Financially, the company will likely need to access capital markets to complete development and commercialization, and any inability to raise adequate funds could impair its ability to advance the pipeline.